Saturday 17 October 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.02
+4.65%
Follow GELS
Gelteq Limited (GELS) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RDHL Redhill Biopharma Ltd. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| INM InMed Pharmaceuticals Inc. compare | n/m |
| SNOA Sonoma Pharmaceuticals, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| YCBD cbdMD, Inc. compare | 41.2× |
| GELS Gelteq Limited | — |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)